KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Total Current Liabilities (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Total Current Liabilities for 8 consecutive years, with $300.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 22.16% year-over-year to $300.8 million, compared with a TTM value of $300.8 million through Dec 2025, up 22.16%, and an annual FY2025 reading of $300.8 million, up 22.16% over the prior year.
  • Total Current Liabilities was $300.8 million for Q4 2025 at Esperion Therapeutics, down from $359.0 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $359.0 million in Q3 2025 and bottomed at $73.4 million in Q4 2021.
  • Average Total Current Liabilities over 5 years is $160.5 million, with a median of $137.7 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities dropped 22.02% in 2021, then skyrocketed 116.45% in 2025.
  • Year by year, Total Current Liabilities stood at $73.4 million in 2021, then grew by 25.84% to $92.3 million in 2022, then skyrocketed by 69.24% to $156.2 million in 2023, then soared by 57.62% to $246.2 million in 2024, then increased by 22.16% to $300.8 million in 2025.
  • Business Quant data shows Total Current Liabilities for ESPR at $300.8 million in Q4 2025, $359.0 million in Q3 2025, and $298.8 million in Q2 2025.